Chris Gillette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chris Gillette has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Delesha Miller Carpenter
Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publications Betsy Sleath
University of North Carolina at Chapel Hill, NC, USA
2 shared publications- Betsy Sleath
University of North Carolina at Chapel Hill, USA
2 shared publications Kimberly Broedel-Zaugg
Department of Pharmaceutical Science and Research, Marshall University School of Pharmacy, Huntington, WV
2 shared publications- Nicole Rockich-Winston
Medical College of Georgia, Augusta University
2 shared publications - Adrian Sandler
Mission Children’s Hospital
1 shared publication
Latest Publications
- 1 January 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (1) , 84-89
Predictors of student performance on the Pharmacy Curriculum Outcomes Assessment at a new school of pharmacy using admissions and demographic data
- 1 January 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (1) , 84-89
Predictors of student performance on the Pharmacy Curriculum Outcomes Assessment at a new school of pharmacy using admissions and demographic data
- 1 September 2016
- Published by Elsevier in Academic Pediatrics
- Vol. 16 (7) , 605-615
Inhaler Technique in Children With Asthma: A Systematic Review
- 1 September 2016
- Published by Elsevier in Academic Pediatrics
- Vol. 16 (7) , 605-615
Inhaler Technique in Children With Asthma: A Systematic Review
- 21 July 2015
- Published by Springer Nature in Osteoporosis International
- Vol. 26 (12) , 2883-2888
Medication persistence in older women with osteoporosis: a pilot study
Most osteoporosis patients stop their medications before they should. Side effects are the most common reason patients in this sample stopped their medication before they told their physician. Physicians should use shared decision-making and discuss side effects of osteoporosis medications with their patients and explain the risks of the medications. The aims of this study were to (a) qualitatively examine reasons for medication non-persistence in osteoporosis, and (b) investigate how medication non-persistence in osteoporosis is associated with outcome expectations, self-efficacy, trust in physicians, and health locus of control. Subjects were recruited from online support groups to answer an anonymous online survey. Subjects were eligible if they (a) were female, (b) were at least 40 years of age, (c) self-identify as having osteoporosis, and (d) have taken at least one medication for osteoporosis. During the survey, subjects completed measures of self-efficacy, outcome expectations, trust in physicians generally, health locus of control, and demographic information. Thirty-four subjects completed the online survey and had usable data. Approximately 82 % (n = 28) of subjects reported discontinuing an osteoporosis medication without first consulting a physician. The most common reason patients discontinued an osteoporosis medication was adverse effects. Subjects were more likely to discontinue their medications when they had poorer outcome expectations on average (p = 0.01), had lower trust in physicians on average (p < 0.0001), and had more of a doctors-centered locus of control (p = 0.03). Self-efficacy, age, insurance, status, and other measures of locus of control were not associated with medication non-persistence. Side effects are a significant concern for women with osteoporosis and may be a cause for medication non-persistence.
- 21 July 2015
- Published by Springer Nature in Osteoporosis International
- Vol. 26 (12) , 2883-2888
Medication persistence in older women with osteoporosis: a pilot study
Most osteoporosis patients stop their medications before they should. Side effects are the most common reason patients in this sample stopped their medication before they told their physician. Physicians should use shared decision-making and discuss side effects of osteoporosis medications with their patients and explain the risks of the medications. The aims of this study were to (a) qualitatively examine reasons for medication non-persistence in osteoporosis, and (b) investigate how medication non-persistence in osteoporosis is associated with outcome expectations, self-efficacy, trust in physicians, and health locus of control. Subjects were recruited from online support groups to answer an anonymous online survey. Subjects were eligible if they (a) were female, (b) were at least 40 years of age, (c) self-identify as having osteoporosis, and (d) have taken at least one medication for osteoporosis. During the survey, subjects completed measures of self-efficacy, outcome expectations, trust in physicians generally, health locus of control, and demographic information. Thirty-four subjects completed the online survey and had usable data. Approximately 82 % (n = 28) of subjects reported discontinuing an osteoporosis medication without first consulting a physician. The most common reason patients discontinued an osteoporosis medication was adverse effects. Subjects were more likely to discontinue their medications when they had poorer outcome expectations on average (p = 0.01), had lower trust in physicians on average (p < 0.0001), and had more of a doctors-centered locus of control (p = 0.03). Self-efficacy, age, insurance, status, and other measures of locus of control were not associated with medication non-persistence. Side effects are a significant concern for women with osteoporosis and may be a cause for medication non-persistence.
- 1 May 2015
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 11 (3) , 468-471
A new lexicon for polypharmacy: Implications for research, practice, and education
- 1 May 2015
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 11 (3) , 468-471
A new lexicon for polypharmacy: Implications for research, practice, and education
- 24 December 2013
- Published by Springer Nature in Community Mental Health Journal
- Vol. 50 (2) , 185-192
Communication About ADHD and Its Treatment During Pediatric Asthma Visits
The objectives of the study were to examine provider-family communication about attention deficit disorder during pediatric asthma visits. Children with asthma, aged 8 through 16 and their parents were recruited at five pediatric practices. All medical visits were audio-taped. There were 296 asthmatic children enrolled into the study and 67 of them also had attention deficit hyperactivity disorder (ADHD). ADHD communication elements suggested by national guidelines were discussed infrequently. Providers were more likely to discuss, educate, and ask one or more questions about ADHD medications if the visit was non-asthma related. Providers included child input into the ADHD treatment regimen during 3 % of visits and they included parent input during 4.5 % of visits. Only one child and three parents asked questions about ADHD. Providers may neglect essential aspects of good ADHD management and communication in children who have ADHD plus another chronic condition such as asthma. Providers should set appropriate treatment expectations, establish target symptoms, and encourage children and parents to ask questions so mutual decision-making can occur.
- 24 December 2013
- Published by Springer Nature in Community Mental Health Journal
- Vol. 50 (2) , 185-192
Communication About ADHD and Its Treatment During Pediatric Asthma Visits
The objectives of the study were to examine provider-family communication about attention deficit disorder during pediatric asthma visits. Children with asthma, aged 8 through 16 and their parents were recruited at five pediatric practices. All medical visits were audio-taped. There were 296 asthmatic children enrolled into the study and 67 of them also had attention deficit hyperactivity disorder (ADHD). ADHD communication elements suggested by national guidelines were discussed infrequently. Providers were more likely to discuss, educate, and ask one or more questions about ADHD medications if the visit was non-asthma related. Providers included child input into the ADHD treatment regimen during 3 % of visits and they included parent input during 4.5 % of visits. Only one child and three parents asked questions about ADHD. Providers may neglect essential aspects of good ADHD management and communication in children who have ADHD plus another chronic condition such as asthma. Providers should set appropriate treatment expectations, establish target symptoms, and encourage children and parents to ask questions so mutual decision-making can occur.
- 17 October 2013
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 52 (12) , 1161-1167
How Often Do Providers Discuss Asthma Action Plans With Children? Analysis of Transcripts of Medical Visits
Objective. To examine how often providers discussed asthma action plans with children and their caregivers and child, clinical, and provider characteristics that were associated with those discussions. Method. This was a cross-sectional analysis of audio-recorded visits between 35 general pediatric providers and 260 children (8-16 years old) with asthma and their caregivers. The visits were transcribed into text. The transcripts were coded for discussions about written asthma action plans. Results. Providers discussed written asthma action plans with 21.0% of children and caregivers. Providers were significantly more likely to discuss asthma action plans when the child was enrolled in Medicaid, the visit was asthma related, the visit was longer, the provider was not White, or more provider education. Conclusion. In our sample, providers rarely discussed action plans with children and their caregivers. Providers should discuss asthma action plans with every child with persistent asthma and their caregivers and revise them regularly.
- 17 October 2013
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 52 (12) , 1161-1167
How Often Do Providers Discuss Asthma Action Plans With Children? Analysis of Transcripts of Medical Visits
Objective. To examine how often providers discussed asthma action plans with children and their caregivers and child, clinical, and provider characteristics that were associated with those discussions. Method. This was a cross-sectional analysis of audio-recorded visits between 35 general pediatric providers and 260 children (8-16 years old) with asthma and their caregivers. The visits were transcribed into text. The transcripts were coded for discussions about written asthma action plans. Results. Providers discussed written asthma action plans with 21.0% of children and caregivers. Providers were significantly more likely to discuss asthma action plans when the child was enrolled in Medicaid, the visit was asthma related, the visit was longer, the provider was not White, or more provider education. Conclusion. In our sample, providers rarely discussed action plans with children and their caregivers. Providers should discuss asthma action plans with every child with persistent asthma and their caregivers and revise them regularly.
- 20 September 2013
- Published by Wiley in Pediatric Pulmonology
- Vol. 49 (8) , 727-733
Provider-caregiver-child discussions about risks associated with asthma control medications: Content and prevalence
Objectives The objectives of this study were to: (1) describe the extent to which general pediatric providers discuss risks associated with asthma control medications with families, and (2) examine factors that are associated with risk discussions. Study Design This study was a cross-sectional secondary analysis of audio taped medical visits involving 35 pediatric providers and 248 children with asthma with their caregivers. Transcripts of the visits were coded for discussions about asthma medication risks. Generalized estimating equations were used to analyze the data. Results Providers discussed asthma control medication risks during 23% of visits. Risks were more likely to be discussed when the visit was longer and when the provider prescribed a new asthma control medication. When providers discussed asthma control medication risks, they were most likely to ask the family general questions and make general statements. Across all of the visits, caregivers asked a total of 16 questions and made a total of 20 statements about risks associated with asthma medications; children asked a total of 3 questions and made two statements about risks associated with asthma control medications. Conclusion Providers discussed risks associated with asthma control medications in less than one-quarter of medical visits. Providers should involve families in discussions about risks associated with medications during every visit to assess potential barriers to medication adherence. Pediatr Pulmonol. 2014; 49:727–733.
- 20 September 2013
- Published by Wiley in Pediatric Pulmonology
- Vol. 49 (8) , 727-733
Provider-caregiver-child discussions about risks associated with asthma control medications: Content and prevalence
Objectives The objectives of this study were to: (1) describe the extent to which general pediatric providers discuss risks associated with asthma control medications with families, and (2) examine factors that are associated with risk discussions. Study Design This study was a cross-sectional secondary analysis of audio taped medical visits involving 35 pediatric providers and 248 children with asthma with their caregivers. Transcripts of the visits were coded for discussions about asthma medication risks. Generalized estimating equations were used to analyze the data. Results Providers discussed asthma control medication risks during 23% of visits. Risks were more likely to be discussed when the visit was longer and when the provider prescribed a new asthma control medication. When providers discussed asthma control medication risks, they were most likely to ask the family general questions and make general statements. Across all of the visits, caregivers asked a total of 16 questions and made a total of 20 statements about risks associated with asthma medications; children asked a total of 3 questions and made two statements about risks associated with asthma control medications. Conclusion Providers discussed risks associated with asthma control medications in less than one-quarter of medical visits. Providers should involve families in discussions about risks associated with medications during every visit to assess potential barriers to medication adherence. Pediatr Pulmonol. 2014; 49:727–733.
- Open Access
- 29 May 2013
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 22 (1) , 69-75
Child and caregiver reported problems in using asthma medications and question-asking during paediatric asthma visits
Objectives: The objectives of the study were to describe the extent to which lay caregivers and children who reported asthma medication problems asked medication questions during their medical visits.Methods: Children with asthma ages 8 through 16 years and their caregivers were recruited at five paediatric practices and their medical visits were audiotape recorded. Children were interviewed after their medical visits and caregivers completed questionnaires. A home visit was conducted 1 month later. Generalized estimating equations were used to analyse the data.Key findings: Two hundred and ninety six families participated. Among those caregivers who reported asthma medication problems, only 35% had asked at least one medication question during the visit. Among children who reported asthma medication problems, only 11% had asked at least one medication question during their consultation. Caregivers and children who reported a problem with their asthma medications were significantly more likely to have asked medication questions if providers had asked more questions about control medications. Children who reported higher asthma management self-efficacy were significantly more likely to have asked an asthma medication question.Conclusions: Only one in three caregivers and one in 10 children who reported an asthma medication problem asked a question during their medical visits and many still reported these problems 1 month later. Pharmacists should encourage caregivers and children to report problems they may be having using their asthma medications.
- 29 May 2013
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 22 (1) , 69-75
Open AccessChild and caregiver reported problems in using asthma medications and question-asking during paediatric asthma visits
Objectives: The objectives of the study were to describe the extent to which lay caregivers and children who reported asthma medication problems asked medication questions during their medical visits.Methods: Children with asthma ages 8 through 16 years and their caregivers were recruited at five paediatric practices and their medical visits were audiotape recorded. Children were interviewed after their medical visits and caregivers completed questionnaires. A home visit was conducted 1 month later. Generalized estimating equations were used to analyse the data.Key findings: Two hundred and ninety six families participated. Among those caregivers who reported asthma medication problems, only 35% had asked at least one medication question during the visit. Among children who reported asthma medication problems, only 11% had asked at least one medication question during their consultation. Caregivers and children who reported a problem with their asthma medications were significantly more likely to have asked medication questions if providers had asked more questions about control medications. Children who reported higher asthma management self-efficacy were significantly more likely to have asked an asthma medication question.Conclusions: Only one in three caregivers and one in 10 children who reported an asthma medication problem asked a question during their medical visits and many still reported these problems 1 month later. Pharmacists should encourage caregivers and children to report problems they may be having using their asthma medications.